INTEGRATED BIOPHARMA INC
For the period ended Jun 30, 2025. Filed Sep 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 23, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Market Information
Effective January 22, 2021, our common stock was upgraded to the OTCQX® Best Market of the OTC Markets Group, Inc. and commenced quotation under the symbol “INBP” on the OTCQX® Best Market. Prior to January 22, 2021, our common stock was quoted on the OTCQB under the symbol INBP.
Set forth below are the high and low bid quotation of the Company’s common stock as quoted on the OTCQX® Best Market, for each of the fiscal quarters in the fiscal years ended June 30, 2025 and 2024. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
| COMMON STOCK | HIGH | LOW |
|---|---|---|
| First Quarter | $0.3325 | $0.1700 |
| Second Quarter | $0.2750 | $0.1962 |
| Third Quarter | $0.2160 | $0.1806 |
| Fourth Quarter | $0.1950 | $0.1730 |
| First Quarter | $0.2300 | $0.1600 |
| Second Quarter | $0.3000 | $0.2300 |
| Third Quarter | $0.3337 | $0.2520 |
| Fourth Quarter | $0.3301 | $0.2490 |
| July 1, 2025 to September 19, 2025 | $0.3350 | $0.2620 |
-15-
Holders
As of September 23, 2025, there were approximately 72 holders of record of the Company’s common stock. This number does not include beneficial owners holding shares through nominee names.
Dividends
We have not declared or paid a dividend with respect to our common stock during the fiscal years ended June 30, 2025 and 2024, nor do we anticipate paying dividends in the foreseeable future.
Equity Compensation Plans
The following table provides information, as of June 30, 2025, about the Company's equity compensation plans:
| Equity Compensation Plan Information | |||
|---|---|---|---|
| Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities | |
| (a) | (b) | reflected in column (a)) | |
| Equity compensation plans approved by security holders | 4,481,350 | $0.39 | 5,659,652 |
| Equity compensation plans not approved by security holders | - | - | - |
| Totals | 4,481,350 | $0.39 | 5,659,652 |
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
During the quarter ended June 30, 2025, neither we nor any “affiliated purchaser,” as that term is defined in Rule 10b-18(a)(3) under the Exchange Act, purchased any of our common stock or other securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.